Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15268241 | 0.90 | ALOX15 (0.42) | TAS1R3TAS1R1TAS1R2ALOX15MMP1 | |
| SCHEMBL19105016 | 0.79 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19543199 | 0.78 | KMT2A (0.37) | TAS1R3TAS1R1TAS1R2ALOX15ALDH1A1 | |
| SCHEMBL16848728 | 0.74 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2ALOX15GAA | |
| SCHEMBL16838219 | 0.71 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL11915912 | 0.71 | CA1 (0.40) | TAS1R3TAS1R1TAS1R2ALDH1A1MAPT | |
| SCHEMBL19105005 | 0.71 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2ALOX15GAA | |
| SCHEMBL12298686 | 0.70 | TAS1R3 (0.37) | TAS1R3TAS1R1TAS1R2ALDH1A1HPGD | |
| SCHEMBL847735 | 0.70 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10261302 | 0.70 | KDM4E (0.38) | TAS1R3TAS1R1TAS1R2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353120-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-9061078-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | TAS1R3 4140/4885TAS1R1 4270/4885TAS1R2 4262/4885 |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | TAS1R3 4140/4885TAS1R1 4270/4885TAS1R2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.